Lixte Biotechnology Holdings, Inc. (Lixte) is a cancer therapeutics and diagnostics company dedicated to bringing improved treatments of human cancers to clinical practice.

Lixte recognizes that competing effectively at the highest level of drug development and creating a successful cancer therapeutics company requires access to multiple highly specialized types of expertise. These disciplines include scientific (molecular and biology, proteomics, biochemistry, chemistry, pharmacology, physiology, and toxicology) financial, regulatory, legal and administrative skills. Lixte’s strategy is to leverage its intellectual resources by acquiring access to the necessary expert knowledge and technical capabilities in each of these disciplines through scientific academic and commercial collaborations, incentivized consultants and advisors, and the purchase of specific technical services rather than by investing in an enormously expensive in-house employee and technical infrastructure that is likely to continuously need modification.

Since February, 2006 we have filed patent applications on the nature and uses of proprietary lead compounds of two distinct classes of drugs having activity against several types of human cancers in the test tube and, in the case of gliobastoma multiforme, the most common and almost uniformly fatal brain tumor of adults, activity in an animal model.